Literature DB >> 23150175

Expression of TWIST1, Snail, Slug, and NF-κB and methylation of the TWIST1 promoter in mammary phyllodes tumor.

Sung-Im Do1, Ji Yeon Kim, So Young Kang, Jae Joon Lee, Jeong Eon Lee, Seok Jin Nam, Eun Yoon Cho.   

Abstract

TWIST1, Slug, Snail, SIP1, and NF-κB are overexpressed in various tumors and associated with metastasis and poor prognosis. In this study, we examined their potential roles in phyllodes tumor (PT). The expression of TWIST1, Snail, Slug, SIP1, and NF-κB in benign (n = 103), borderline (n = 38), and malignant (n = 38) PTs was examined by immunostaining. The methylation status of the TWIST1 promoter was analyzed by methylation-specific PCR. We detected high expression levels of TWIST1 in 47.4 % of borderline/malignant PTs and 31.1 % of benign PTs, Slug in 64 % of borderline/malignant PTs and 62.1 % of benign PTs, epithelial SIP1 in 75.0 % of borderline/malignant PTs and 86.3 % of benign PTs, stromal SIP1 in 35.5 % of borderline/malignant PTs and 22.3 % of benign PTs, and NF-κB in 63.2 % of borderline/malignant PTs and 52.4 % of benign PTs. Snail expression was detected in all cases. A high expression of TWIST1 (p = 0.026) and TWIST1 promoter methylation (p = 0.000) were significantly more frequent in borderline/malignant PTs than in benign PTs. Moreover, a high expression of at least four of the five antibodies was more commonly observed in borderline/malignant PTs than in benign PTs (p = 0.026). However, no relationship was found between the expression of TWIST1 or the other proteins examined and the clinical outcome. Our results suggest that a high expression of TWIST1 and related proteins plays a pivotal role in the malignant progression of PT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150175     DOI: 10.1007/s13277-012-0569-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  42 in total

1.  Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer.

Authors:  H-F Yuen; C-W Chua; Y-P Chan; Y-C Wong; X Wang; K-W Chan
Journal:  Histopathology       Date:  2007-04       Impact factor: 5.087

2.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 3.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

4.  Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.

Authors:  Zhi-Qiang Ling; Pei Li; Ming-Hua Ge; Xuan Zhao; Fu-Jun Hu; Xian-Hua Fang; Zi-Min Dong; Wei-Min Mao
Journal:  Int J Mol Med       Date:  2011-03-03       Impact factor: 4.101

5.  Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition.

Authors:  Terence K Lee; Ronnie T P Poon; Anthony P Yuen; Ming Tat Ling; Wei Kei Kwok; Xiang Hong Wang; Yong Chuan Wong; Xin Yuan Guan; Kwan Man; King Lok Chau; Sheung Tat Fan
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice.

Authors:  Kenoki Ohuchida; Kazuhiro Mizumoto; Seiji Ohhashi; Hiroshi Yamaguchi; Hiroyuki Konomi; Eishi Nagai; Koji Yamaguchi; Masazumi Tsuneyoshi; Masao Tanaka
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

7.  Unexpected functional redundancy between Twist and Slug (Snail2) and their feedback regulation of NF-kappaB via Nodal and Cerberus.

Authors:  Chi Zhang; Michael W Klymkowsky
Journal:  Dev Biol       Date:  2009-04-21       Impact factor: 3.582

8.  Clinicopathological significance of Sip1-associated epithelial mesenchymal transition in non-small cell lung cancer progression.

Authors:  Naoko Miura; Tokujiro Yano; Fumihiro Shoji; Daigo Kawano; Tomoyoshi Takenaka; Kensaku Ito; Yosuke Morodomi; Ichiro Yoshino; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

9.  Increased p53 protein expression in malignant mammary phyllodes tumors.

Authors:  Gary M K Tse; Thomas C Putti; Fred Y L Kung; Richard A Scolyer; Bonita K B Law; Tai-Shing Lau; C Soon Lee
Journal:  Mod Pathol       Date:  2002-07       Impact factor: 7.842

10.  Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer.

Authors:  Eelke H Gort; Karijn P M Suijkerbuijk; Suzan M Roothaan; Venu Raman; Marc Vooijs; Elsken van der Wall; Paul J van Diest
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

View more
  5 in total

1.  (-)-Epigallocatechin-3-gallate inhibits nasopharyngeal cancer stem cell self-renewal and migration and reverses the epithelial-mesenchymal transition via NF-κB p65 inactivation.

Authors:  Ya-Jun Li; Shun-Long Wu; Song-Mei Lu; Fang Chen; Ying Guo; Sheng-Min Gan; Yan-Long Shi; Shuang Liu; Shao-Lin Li
Journal:  Tumour Biol       Date:  2014-12-07

Review 2.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20

3.  Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells.

Authors:  Zhongye Wang; Zhenyuan Zhai; Xiulan Du
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

4.  Expression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breast.

Authors:  Xiaolong Feng; Lin Zhao; Honghong Shen; Xiaozhen Liu; Yang Yang; Shuhua Lv; Yun Niu
Journal:  Oncotarget       Date:  2017-05-16

5.  Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias.

Authors:  Yutaka Suehiro; Shinichi Hashimoto; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Tomomi Hoshida; Toshihiko Matsumoto; Yuko Yamaoka; Taro Takami; Isao Sakaida; Takahiro Yamasaki
Journal:  Oncotarget       Date:  2018-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.